Top 3 Picks
2026 Outlook
Sector trends for 2026 center on AI-integrated monitoring, expanded neuromodulation indications, and minimally invasive procedures driving mid-single-digit revenue growth. Reimbursement tailwinds and international expansion should favor scaled manufacturers, while smaller caps with scores above 60 offer higher-beta opportunities. Overall, the top-10 average score of 52.4 points to selective upside in a stabilizing macro environment.
Complete Rankings
| Rank | Stock | Score | Price | Market Cap |
|---|---|---|---|---|
|
1
|
LivaNova PLC Ordinary Shares
|
66.9 | $81.92 | $2.8B |
|
2
|
Integer Holdings Corporation
|
61.2 | $126.50 | $3.6B |
|
3
|
Masimo Corporation
|
60.3 | $179.95 | $7.7B |
|
4
|
CONMED Corporation
|
56.6 | $49.32 | $1.5B |
|
5
|
BioLife Solutions Inc.
|
52.0 | $35.25 | $1.3B |
|
6
|
Medtronic plc
|
50.9 | $94.17 | $121.6B |
|
7
|
Axogen, Inc. Common Stock
|
50.2 | $48.28 | $822M |
|
8
|
TransMedics Group, Inc. Common Stock
|
46.3 | $89.98 | $3.9B |
|
9
|
Soleno Therapeutics, Inc. Common Stock
|
44.5 | $53.01 | $3.2B |
|
10
|
Solana Company Class A Common Stock (DE)
|
35.9 | $2.24 | $582M |
In-Depth Analysis: Top Electromedical Stocks
LIVN
UK-based LivaNova was born of a combination of Cyberonics in the US and Sorin in Italy. The medical-device firm is primarily focused on cardiopulmonary solutions (with heart-lung machines and oxygenation equipment) as well as neuromodulation devices for treatment-resistant epilepsy and depression. Following the merger, LivaNova divested its cardiac rhythm management, heart valve, and extracorporeal membrane oxygenation businesses. It derives roughly …
LivaNova matters in the electromedical sector as a provider of cardiopulmonary solutions including heart-lung machines and oxygenation equipment, paired with neuromodulation devices for treatment-resistant epilepsy and depression following the Cyberonics-Sorin merger.
LivaNova shows solid financial health via a 12.8% profit margin and 15.4% ROE alongside 10.8% revenue growth, with its P/E of 24.0 indicating reasonable valuation for the sector.
Investors should consider LIVN in 2026 due to its 10.8% revenue growth and 66.9 Tradestie Score, fueled by rising demand for neuromodulation in epilepsy and depression. The cardiopulmonary portfolio adds stability while the 15.4% ROE supports margin expansion from global device adoption. A P/E of 24.0 offers entry at moderate multiples ahead of potential market share gains.
ITGR
Integer Holdings Corp is a manufacturer of medical device components used by original equipment manufacturers in the medical industry. The company also develops batteries used in nonmedical applications in the energy, military, and environmental markets. The firm organizes itself into one segment and derives its revenues from three product lines: Cardio & Vascular, Cardiac Rhythm Management & Neuromodulation and Other …
Integer Holdings Corporation supplies critical medical device components to OEMs, serving as a foundational player in the electromedical supply chain for devices used in diagnostics and therapies.
The company reports a 7.0% profit margin and 7.5% ROE alongside -2.6% revenue growth, reflecting moderate returns on equity with limited top-line momentum, while the 34.4 P/E ratio signals valuation pressure relative to current performance.
ITGR's Tradestie Score of 61.2/100 highlights operational stability that could support recovery in medical component demand by 2026. The single-segment focus on OEM supply enables targeted efficiency gains despite recent revenue softness. Investors may target the stock for sector tailwinds in electromedical applications as P/E compression creates entry points from current levels.
MASI
Masimo Corp is a technology company. The company's segment includes healthcare and non-healthcare. The healthcare business segment is a key revenue driver, develops, manufactures, and markets a variety of noninvasive patient monitoring technologies, hospital automation and connectivity solutions, remote monitoring devices and consumer health products. Its non-healthcare segment includes consumer audio business develops, manufactures, markets sells and licenses premium and …
Masimo Corporation leads in the Electromedical sector with its noninvasive patient monitoring technologies and hospital automation solutions, which drive efficiency and outcomes in healthcare settings. Its healthcare segment remains the primary revenue engine amid rising demand for connectivity in medical devices.
Masimo reports a 4.9% profit margin alongside a strong 25.0% ROE and 8.5% revenue growth, indicating efficient equity utilization despite margin pressures from operational investments. The 44.2 P/E ratio reflects premium valuation tied to its electromedical expansion potential.
With 25.0% ROE and 8.5% revenue growth supporting scalable healthcare technologies, MASI presents an attractive entry for 2026 as hospital automation demand rises. Its 60.3 Tradestie Score and sector positioning suggest upside from sustained monitoring adoption, outweighing the 4.9% margin in a growth-oriented valuation at 44.2 P/E.
CNMD
Conmed Corp is a Utica, New York-based medical equipment company that focuses on sports medicine procedures and general surgeries. The Company's products are used by surgeons and other healthcare professionals in a variety of specialties including orthopedics, general surgery, gynecology, thoracic surgery and gastroenterology. Geographically operates in USA, Europe, Middle East & Africa, Asia Pacific and North America. Majority is …
CONMED Corporation matters in the Electromedical sector through its specialized electrosurgical and orthopedic devices used in orthopedics, general surgery, gynecology, and thoracic procedures, enabling minimally invasive techniques across surgical specialties.
CONMED's 4.1% profit margin and 5.5% ROE reflect limited profitability and returns, while 0.3% revenue growth and a 26.7 P/E ratio indicate stagnant top-line performance and premium valuation relative to financial health.
Investors should consider CNMD in 2026 for its entrenched role in sports medicine and electrosurgical markets that align with electromedical demand growth. Despite current 0.3% revenue growth, potential margin recovery above the 4.1% level and ROE expansion from 5.5% could drive re-rating from the 26.7 P/E as procedural volumes increase. The 56.6/100 Tradestie Score positions the stock for upside in a recovering surgical equipment cycle.
BLFS
BioLife Solutions Inc is a life sciences company that develops, manufactures, and markets bioproduction products and services that are designed to improve quality and de-risk biologic manufacturing, distribution, and transportation in the cell and gene therapy ("CGT") industry. The company provides solutions such as Cell Processing, Cold Chain, and Thawing. The company generates the majority of its revenue from Cell …
BioLife Solutions Inc. matters in the Electromedical sector through its bioproduction products and services that improve quality and de-risk manufacturing, distribution, and transportation for the cell and gene therapy industry.
BioLife Solutions reports a 54.4% profit margin alongside 21.5% revenue growth, indicating robust margins and top-line expansion, while its 12.8% ROE and 35.5 P/E reflect moderate equity returns at a premium valuation.
Investors should consider BLFS in 2026 as its 21.5% revenue growth and 54.4% profit margins align with accelerating CGT demand; the company's focus on de-risking biologic processes positions it for market share gains that could lift ROE above 12.8% and support the 35.5 P/E multiple as adoption scales.
MDT
One of the largest medical-device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, transcatheter heart valves, stents, insulin pumps, spinal fixation devices, neurovascular products, advanced energy, ablation laser therapy, and surgical tools. The company primarily markets its products to healthcare institutions and physicians in the United States, Western Europe, and Japan. Foreign …
Medtronic ranks among the largest electromedical companies, developing and manufacturing devices for chronic diseases including pacemakers, defibrillators, transcatheter heart valves, stents, insulin pumps, spinal fixation devices, and neurovascular products.
Medtronic reports a 13.9% profit margin and 9.8% ROE with 13.7% revenue growth, reflecting stable earnings and operational scale, while its 24.7 P/E ratio indicates measured valuation against current earnings.
Medtronic's 13.7% revenue growth and leadership across cardiovascular and diabetes device segments position it for continued expansion in 2026 driven by aging demographics and procedure volume recovery. Its diversified portfolio in high-demand areas such as transcatheter valves and neurovascular products supports margin stability at 13.9%. At a 24.7 P/E, the shares present a reasonable entry point for exposure to sector growth.
AXGN
Axogen Inc is engaged in the science, development, and commercialization of technologies for peripheral nerve regeneration and repair. The company provides clinically, economically effective repair solutions for surgeons and health care providers. Its products include Avance Nerve Graft, Axoguard Nerve Connector, Axoguard Nerve Protector, Axoguard Nerve Cap and Avive Soft Tissue Membrane. It also offers an Axotouch Two-Point Discriminator used …
Axogen leads in peripheral nerve regeneration technologies within the electromedical sector, commercializing solutions such as Avance Nerve Graft and Axoguard products that enable clinically effective surgical repairs for surgeons and healthcare providers.
Axogen reports a -13.4% profit margin and -18.2% ROE, indicating persistent unprofitability from commercialization investments, while 23.1% revenue growth demonstrates expanding adoption of its nerve repair portfolio.
Axogen's 23.1% revenue growth highlights accelerating demand in the specialized peripheral nerve repair market, which could drive margin expansion from current -13.4% levels by 2026 through increased scale and operating leverage. The company's focused electromedical technologies position it to gain share in a high-growth niche, supporting potential valuation upside for investors targeting 2026 profitability inflection.
TMDX
TransMedics Group Inc is a commercial-stage medical technology company transforming organ transplant therapy for end-stage organ failure patients across multiple disease states. It has developed the Organ Care System(OCS) to comprehensively address the limitations of cold storage. The OCS is a portable organ perfusion, optimization and monitoring system that utilizes technology to replicate near-physiologic conditions for donor organs outside of …
TransMedics' Organ Care System (OCS) directly tackles cold storage limitations in organ preservation, establishing the company as a pivotal innovator in the electromedical sector for end-stage organ failure treatments across multiple disease states.
A 22.7% profit margin paired with 36.3% ROE reflects strong operational efficiency and capital returns, while 20.7% revenue growth supports financial health at a P/E of 21.9.
TMDX offers investors exposure to scalable OCS adoption in the growing transplant market, where 20.7% revenue growth and 36.3% ROE position the company for margin expansion through 2026. The current P/E of 21.9 provides a reasonable entry point relative to projected earnings increases from broader clinical utilization. Strong profitability metrics indicate potential for sustained valuation upside as electromedical demand rises.
SLNO
Soleno Therapeutics Inc is a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases. Its product candidate DCCR (Diazoxide Choline) Extended-Release tablets, is a proprietary extended-release formulation of a crystalline salt of diazoxide. DCCR has demonstrated the ability to activate the KATP channel in the brain, pancreas, and fat tissue.
Soleno Therapeutics develops DCCR extended-release tablets for rare diseases, positioning it as an innovator in the Electromedical sector through targeted therapeutics that address unmet medical needs with demonstrated clinical potential.
Soleno reports a 33.7% profit margin and 26.4% ROE, reflecting strong operational efficiency and returns on equity, while its 27.5 P/E ratio indicates earnings are valued at a moderate multiple relative to sector peers.
SLNO offers upside in 2026 as DCCR advances toward commercialization in rare disease markets, leveraging its 33.7% profit margin and 26.4% ROE for scalable growth. The 44.5/100 Tradestie Score highlights undervaluation potential if clinical milestones drive revenue expansion beyond current earnings. Investors can target the stock for exposure to high-margin biopharma assets with proven financial health.
HSDT
Helius Medical Technologies Inc is a neurotech company focused on neurological wellness. The company's purpose is to develop, license, or acquire non-invasive technologies targeted at reducing symptoms of neurological disease or trauma. The company's product, known as the Portable Neuromodulation Stimulator (PoNS) is authorized for sale in Canada as a class II, a non-implantable medical device intended for use as …
Helius Medical Technologies develops non-invasive Portable Neuromodulation Stimulator technology to reduce symptoms of neurological disease or trauma, establishing relevance in the electromedical sector through targeted neurotech innovation.
ROE of -179.0% and P/E of 0.0 reflect deep unprofitability and negative earnings, while 5774.4% revenue growth signals early-stage scaling that has not yet improved financial health.
Explosive revenue growth positions HSDT for potential market share gains in electromedical neurotech if 2026 commercialization milestones are met. A low Tradestie Score of 35.9/100 combined with sector demand for non-invasive neurological solutions could drive re-rating upon path-to-profitability evidence. Continued top-line expansion may attract investors seeking high-growth turnaround plays by late 2026.
Methodology
Stocks are ranked using the Tradestie Score, a proprietary 0-100 rating that combines fundamental quality (profitability, balance sheet strength), growth metrics (revenue and earnings growth), valuation (P/E, PEG ratio), and momentum factors. Scores are updated daily based on the latest market data. Learn more about our methodology.